CΥP2C19 genetic mutation in North Indians

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 3, 2000, Pages 328-335

  Lamba, Jatinder K ^a   Dhiman, Radha K ^a   Kohli, Krishan K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYOMEPRAZOLE; AMOXICILLIN; CYTOCHROME P450 2C19; DIAZEPAM; DRUG METABOLITE; HEXOBARBITAL; IMIPRAMINE; LANSOPRAZOLE; MEPHENYTOIN; METHYLPHENOBARBITAL; OMEPRAZOLE; PROGUANIL; PROPRANOLOL; UNCLASSIFIED DRUG; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; GENETICS; INDIA; METABOLISM; NUCLEIC ACID PROBE; POPULATION GENETICS;

ALLELES; ANTISENSE ELEMENTS (GENETICS); ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETICS, POPULATION; GENOTYPE; HUMANS; INDIA; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 0033623143     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.109365     Document Type: Article

References (34)

1. Molecular mechanisms of genetic polymorphisms of drug metabolism
2. Genetic polymorphism of hepatic cytochrome P450 2C19 in North Indian subjects
3. Genetic polymorphism of CYP2D6 in North Indian subjects
4. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19(m1) in exon 5 and CYP2C19(m2) in exon 4, in Japanese subjects
5. Hydroxylation polymorphisms of debrisoquin and mephenytoin in European populations
6. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
7. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics
8. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu
9. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19
10. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcen Ann Intern Med
11. Identification of new human CYP2C19 alleles (CYP2C19(*)6 and CYP2C19(*)2B) in a Caucasian poor metabolizer of mephenytoin
12. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin
13. Nomenclature for human CYP2D6 alleles
14. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
15. The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos
16. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype
17. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese
18. CYP2D6 multiallelism
19. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
20. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism
21. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily
22. Phenotyping of CYP2C19 with enantioselective HPLC-quantification of R- and S-mephenytoin and comparison with intron4/exon5 G to A site mutation
23. S-mephenytoin hydroxylation phenotypes in a Jordanian population
24. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population
25. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: Indications for oral contraceptive-related gender differences
26. Evidence for the effect of gender on activity of S-mephenytoin 4'-hydroxylation (CYP2C19) in a Chinese population
27. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P4502C19) in a Shona population of Zimbabwe
28. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity
29. Canadian native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies
30. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population
31. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population
32. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians
33. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population
34. Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP2C9 in a Japanese population